EGRX Eagle Pharmaceuticals Inc

Price (delayed)

$21.53

Market cap

$281.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$336.29M

Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements ...

Highlights
The company's equity rose by 12% YoY and by 4% QoQ
Eagle Pharmaceuticals's quick ratio has decreased by 29% YoY but it has increased by 22% from the previous quarter
The company's revenue fell by 16% QoQ but it rose by 8% YoY
The EPS has plunged by 108% from the previous quarter and by 107% YoY
The net income has dropped by 107% since the previous quarter and by 107% year-on-year

Key stats

What are the main financial stats of EGRX
Market
Shares outstanding
13.09M
Market cap
$281.86M
Enterprise value
$336.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
1.05
EV/EBIT
17.52
EV/EBITDA
9.05
EV/Sales
1.26
Earnings
Revenue
$267.04M
EBIT
$19.2M
EBITDA
$37.16M
Free cash flow
$33.73M
Per share
EPS
-$0.21
Free cash flow per share
$2.58
Book value per share
$18.56
Revenue per share
$20.45
TBVPS
$19.62
Balance sheet
Total assets
$414.18M
Total liabilities
$171.33M
Debt
$76.33M
Equity
$242.85M
Working capital
$94.68M
Liquidity
Debt to equity
0.31
Current ratio
1.97
Quick ratio
1.4
Net debt/EBITDA
1.46
Margins
EBITDA margin
13.9%
Gross margin
68.4%
Net margin
-1%
Operating margin
12.3%
Efficiency
Return on assets
-0.7%
Return on equity
-1.1%
Return on invested capital
12%
Return on capital employed
6.1%
Return on sales
7.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EGRX stock price

How has the Eagle Pharmaceuticals stock price performed over time
Intraday
4.01%
1 week
5.28%
1 month
-23.63%
1 year
-53.23%
YTD
-26.34%
QTD
-24.11%

Financial performance

How have Eagle Pharmaceuticals's revenue and profit performed over time
Revenue
$267.04M
Gross profit
$182.56M
Operating income
$32.9M
Net income
-$2.67M
Gross margin
68.4%
Net margin
-1%
Eagle Pharmaceuticals's net margin has shrunk by 109% QoQ and by 107% YoY
The net income has dropped by 107% since the previous quarter and by 107% year-on-year
Eagle Pharmaceuticals's operating income has shrunk by 59% QoQ and by 50% YoY
The operating margin has dropped by 54% year-on-year and by 52% since the previous quarter

Growth

What is Eagle Pharmaceuticals's growth rate over time

Valuation

What is Eagle Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.16
P/S
1.05
EV/EBIT
17.52
EV/EBITDA
9.05
EV/Sales
1.26
The EPS has plunged by 108% from the previous quarter and by 107% YoY
EGRX's P/B is 67% below its 5-year quarterly average of 3.5 and 36% below its last 4 quarters average of 1.8
The company's equity rose by 12% YoY and by 4% QoQ
EGRX's price to sales (P/S) is 67% lower than its 5-year quarterly average of 3.2 and 30% lower than its last 4 quarters average of 1.5
The company's revenue fell by 16% QoQ but it rose by 8% YoY

Efficiency

How efficient is Eagle Pharmaceuticals business performance
Eagle Pharmaceuticals's ROA has plunged by 107% from the previous quarter and by 105% YoY
Eagle Pharmaceuticals's return on equity has shrunk by 107% QoQ and by 106% YoY
EGRX's return on invested capital has dropped by 80% year-on-year and by 75% since the previous quarter
The ROS has plunged by 67% YoY and by 65% from the previous quarter

Dividends

What is EGRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EGRX.

Financial health

How did Eagle Pharmaceuticals financials performed over time
Eagle Pharmaceuticals's total assets is 142% higher than its total liabilities
The total liabilities has soared by 64% year-on-year
Eagle Pharmaceuticals's quick ratio has decreased by 29% YoY but it has increased by 22% from the previous quarter
Eagle Pharmaceuticals's debt is 69% lower than its equity
Eagle Pharmaceuticals's debt to equity has soared by 182% YoY and by 15% from the previous quarter
Eagle Pharmaceuticals's debt has increased by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.